Med Bull Sisli Etfal Hosp. 2022; 56(1): 62-69 | DOI: 10.14744/SEMB.2021.85595

Pediatric Patients with COVID-19: A Retrospective Single-Center Experience

Ayse Sahin¹, Nazan Dalgic¹, Mesut Sancar², Emel Celebi Congur¹, Mehmet Kemal Kanik¹, Sibel Degim Ilgar³, Banu Bayraktar³, Haci Mustafa Ozdemir^4
1Department of Pediatric Infectious Diseases, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences Turkey, Istanbul, Turkey
²Department of Clinical Pharmacy, Marmara University Faculty of Pharmacy, Istanbul, Turkey
³Department of Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences Turkey, Istanbul, Turkey
⁴Department of Ortopedics and Traumatology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences Turkey, Istanbul, Turkey

Objectives: The pandemic of coronavirus disease 2019 (COVID-19) is still effective all over the world. Compared to adults, data on pediatric patients are limited. In this study, we aimed to retrospectively examine the demographic, clinical, and laboratory characteristics of pediatric patients who were followed up with the diagnosis of COVID-19 in the first 3 months of the pandemic in our hospital.
Methods: A total of 190 patients, aged 1 month–18 years, who were followed up with a definite/probable diagnosis of COVID-19, who were treated in the Pediatric Infection Clinic, were included in the study. The demographic features, clinical characteristics, and laboratory findings of the patients were retrospectively analyzed from their electronic medical records.
Results: Eighty (42.1%) of the patients were laboratory confirmed (Polymerase chain reaction positive in nasopharyngeal swab). Mean age was 72 (2–216 months) and 102 (53.7%) patients were female. Family contact history was present in 115 (60.5%) patients. The patients were classified as asymptomatic (5.8%), mild (73.2%), moderate (18.4%), and severe/critical (2.6%) according to the severity of the disease. The most common symptoms were cough (71.1%) and fever (51.1%). Hydroxychloroquine alone or in combination was the most commonly used agent.
Conclusion: In our study, in which we examined the pediatric COVID-19 patients, most of the patients had a mild clinical course, but there were applications with different clinical pictures such as acute appendicitis. Therefore, COVID-19 infection, which is still very unknown, will continue to surprise us with both changing treatment protocols and clinical presentations such as multisystem inflammatory syndrome in children.

Keywords: Children, COVID-19, hydroxychloroquine, multisystem inflammatory syndrome in children, Turkey

---

COVID-19’lu Çocuk Hastalar: Geriye Dönük Tek Merkez Deneyimi

Ayse Sahin¹, Nazan Dalgic¹, Mesut Sancar², Emel Celebi Congur¹, Mehmet Kemal Kanik¹, Sibel Degim Ilgar³, Banu Bayraktar³, Haci Mustafa Ozdemir^4
1Saðlýk Bilimleri Üniversitesi Türkiye, Þiþli Hamidiye Etfal Eðitim ve Araþtýrma Hastanesi, Çocuk Enfeksiyon Hastalýklarý Anabilim Dalý, Ýstanbul
²Marmara Üniversitesi Eczacýlýk Fakültesi Klinik Eczacýlýk Anabilim Dalý, Ýstanbul
³Saðlýk Bilimleri Üniversitesi Türkiye, Þiþli Hamidiye Etfal Eðitim ve Araþtýrma Hastanesi, Klinik Mikrobiyoloji Anabilim Dalý, Ýstanbul
⁴Saðlýk Bilimleri Üniversitesi Türkiye, Þiþli Hamidiye Etfal Eðitim ve Araþtýrma Hastanesi, Ortopedi ve Travmatoloji Anabilim Dalý, Ýstanbul

Amaç: Coronavirus disease 2019 (COVID-19) pandemisi, halen tüm dünyada etkisini sürdürmektedir. Eriþkinlere kýyasla çocuk hastalarla ilgili veriler sýnýrlýdýr. Bu çalýþmada, hastanemizde pandeminin ilk üç ayýnda COVID-19 tanýsý ile takip edilen çocuk hastalarýn demografik, klinik, laboratuvar özelliklerinin retrospektif olarak incelenmesi amaçlanmýþtýr.
Yöntem: Çocuk Enfeksiyon Kliniðinde ayaktan/yatarak tedavi gören kesin/olasý COVID-19 tanýsý ile takip edilen 1 ay-18 yaþ arasý 190 hasta çalýþmaya dahil edildi. Hastalarýn, demografik yapýlarý, klinik özellikleri ve laboratuvar bulgularý elektronik týbbi kayýtlarýndan retrospektif olarak incelendi.
Bulgular: Hastalarýn 80 (% 42.1)’i laboratuvar ile (nazofarengeal sürüntüde PCR pozitif) doðrulanmýþtý. Ortalama yaþ 72 ( 2-216 ay), 102 (% 53.7) hasta kýz idi. Aile içi temas öyküsü, 115 (%60.5) hastada mevcuttu. Hastalar hastalýðýn þiddetine göre asemptomatik (%5.8), hafif (%73.2), orta (%18.4) ve aðýr/kritik (%2.6) olarak sýnýflandýrýldý. En sýk görülen semptom, öksürük (%71.1) ve ateþ (% 51.1) idi. Hydroxychloroquine tek ya da kombine olarak en sýk kullanýlan ajandý.
Sonuç: Çocuk yaþ grubu COVID-19 hastalarýný incelediðimiz çalýþmamýzda, hastalarýn büyük kýsmý hafif klinik seyir göstermekteydi ancak akut appandisit gibi farklý klinik tablo ile baþvurularda mevcuttu. Bu nedenle halen çok bilinmezi olan COVID-19 enfeksiyonu gerek deðiþen tedavi protokolleri gerekse MIS-C gibi klinik prezentasyonlarý ile bizi þaþýrtmaya devam edecektir. (SETB-2021-06-197)

Anahtar Kelimeler: COVID-19, çocuklar, hidroksiklorokin, MIS-C, Türkiye

---

CITE